Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue 5, 1999, Pages 681-686

  Eugster, Erica A ^a,b   Shankar, Ravi ^a   Feezle, Lori K ^a   Pescovitz, Ora H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

McCune Albright syndrome; Precocious puberty; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; TESTOLACTONE;

ALBRIGHT SYNDROME; ARTICLE; BODY HEIGHT; BONE AGE; BONE MATURATION; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; NEGRO; PATIENT COMPLIANCE; PRECOCIOUS PUBERTY; PRESCHOOL CHILD;

EID: 0032854049     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1999.12.5.681     Document Type: Article

References (36)

1. McCune DJ, Bruch H. Osteitis fibrosa cystica: The case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Transactions of the Society for Pediatric Research, Annual Meeting, May 1936. Am J Dis Child 1936; 52: 725.
2. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 1937; 216: 727-740.
3. Aarskog D, Tveteraas E. McCune-Albright's syndrome following adrenalectomy for Cushing's syndrome in infancy. J Pediatr 1968; 73: 89-96.
4. Danon M, Robboy SJ, Kim S, Scully R, Crawford JD. Cushing syndrome, sexual precocity, and polyostotic fibrous dysplasia (Albright syndrome) in infancy. J Pediatr 1975; 87: 917-921.
5. D'Armiento M, Reda G, Camagna A, Tardella L. McCune-Albright syndrome: Evidence for autonomous multiendocrine hyperfunction. J Pediatr 1983; 102: 584-586.
6. Cuttler L, Jackson JA, Uz-Zafar SM, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989; 68: 1148-1154.
7. Foster CM. Endocrine manifestations of McCune-Albright syndrome. Endocrinologist 1993; 3: 359-364.
8. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM. Severe endocrine and non-endocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs. J Pediatr 1993; 123: 509-518.
9. Benedict PH. Sex precocity and polyostotic fibrous dysplasia. Am J Dis Child 1966; 111: 426-429.
10. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Speigel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-1695.
11. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992; 89: 5152-5156.
12. Shenker A, Weinstein LS, Sweet DE, Spiegel AM. An activating Gsα mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994; 79: 750-755.
13. Schnabel P, Bohm M. Mutations of signal-transducing G proteins in human disease. J Mol Med 1995; 73: 221-228.
14. Lefkowitz RJ. Clinical implications of basic research. N Engl J Med 1995; 332: 186-187.
15. Spiegel AM. The molecular basis of disorders caused by defects in G proteins. Horm Res 1997; 47: 89-96.
16. Ehrhardt AA, Meyer-Bahlburg HFL, Bell JJ, Cohen SF, Healey JM, Steil R, Feldman JF, Morishima A, New MI. Idiopathic precocious puberty in girls: Psychiatric follow-up in adolescence. J Am Acad Child Adolesc Psych 1984; 23: 23-33.
17. Ehrhardt AA, Meyer-Bahlburg HFL. Idiopathic precocious puberty in girls: Long-term effects on adolescent behavior. Acta Endocrinol (Copenh) 1986; Suppl 279: 247-253.
18. Foster CM, Feuillan P, Padmanabhan V, Pescovitz OH, Beitins IZ, Comite F, Shawker TH, Loriaux DL, Cutler GB. Ovarian function in girls with McCune-Albright syndrome. Pediatr Res 1986; 20: 859-863.
19. Foster CM, Ross JL, Shawker T, Pescovitz OH, Loriaux DL, Cutler GB, Comite F. Absence of pubertal gonadotropin secretion in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 1984; 58: 1161-1165.
20. Comite F, Shawker TH, Pescovitz OH, Loriaux DL, Cutler GB. Cyclical ovarian function resistant to treatment with an analogue of luteinizing hormone releasing hormone in McCune-Albright syndrome. N Engl J Med 1984; 311: 1032-1036.
21. Foster CM, Comite F, Pescovitz OH, Ross JL, Loriaux DL, Cutler GB. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 1984; 59: 801-805.
22. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.N Engl J Med 1986; 315: 1115-1119.
23. Feuillan PB, Jones J, Cutler GB. Long term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77: 647-651.
24. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd Ed. Stanford, CA: Stanford University Press, 1959.
25. Lippman ME. The NIH consensus development conference for breast cancer. 1986 NCI Monogr.; 1.
26. Friedl A, Jordan VC. What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 1994; 31: 27-39.
27. Metzger DL, Kerrigan JR. Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of exogenous estrogens during male adolescence. J Clin Endocrinol Metab 1994; 79: 513-518.
28. Maddalozzo J, Tenta LT, Hutchinson LR, Crawford SE, Morse DS. Juvenile fibromatosis: hormonal receptors. J Pediatr Otorhinolaryngol 1993; 25: 191-199.
29. th Ed. St. Louis, MO: Mosby, 1994; 370-371.
30. Kucukaydin M, Kurtoglu S, Okur H, Patiroglu TE, Zorlu M, Gunduz Z, Kazez A. Virginal hypertrophy: Case report. Turkish J Pediatr 1994; 36: 243-248.
31. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res 1997; 48: 155-163.
32. Sadovsky Y, Adler S. Editorial: Selective modulation of estrogen receptor action. J Clin Endocrinol Metab 1998; 83: 3-5.
33. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998; 83: 6-13.
34. Fisher B, Costantino JP, Wickerman DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Can Inst 1998; 90: 1371-1388.
35. MacMahon HE. Albright's syndrome - thirty years later. Pathol Ann 1971; 6: 81-146.
36. Scanlon, EF, Burkett FE, Sener SF, Green OC, Traisman HS, Marr TJ, Victor TA, Christ ML. Breast carcinoma in an 11-year-old girl with Albright's syndrome. Breast 1980; 6: 6-9.